AB122 Platform Study

Required: PD-L1 (CD274) overexpression (≥ 50% tumor proportion score)

Has PD-L1 (≥ 50% tumor proportion score) in tumor tissue sample as determined at a local laboratory.

Required: PD-L1 (CD274) overexpression (≥ 50% tumor proportion score)

Has PD-L1 (≥ 50% tumor proportion score) in tumor tissue sample as determined at a local laboratory (except for tolerability part).

Required: KRAS wild-type

RAS status must have been previously determined (mutant or wild-type) based on local assessment of tumor biopsy; Wild type is defined as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (exon 2, 3 and 4) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type.

Required: NRAS wild-type

RAS status must have been previously determined (mutant or wild-type) based on local assessment of tumor biopsy; Wild type is defined as v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) (exon 2, 3 and 4) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) (exon 2, 3 and 4) wild type.

Must have received: systemic chemotherapy — advanced or metastatic PDAC

Has disease progression after or intolerant to one prior systemic chemotherapy for advanced or metastatic disease

Must have received: systemic chemotherapy — advanced or metastatic CRC

Has been received one regimen of standard chemotherapy for advanced or metastatic disease, and was refractory or intolerant to the chemotherapy

Must have received: systemic chemotherapy — advanced or metastatic non-squamous NSCLC

Has been received one or two regimen of standard chemotherapy for advanced or metastatic disease, and was refractory or intolerant to the standard treatment

Must have received: immune checkpoint inhibitor (anti PD-1 antibodies, anti PD-L1 antibodies, anti CTLA-4 antibodies) — advanced or metastatic non-squamous NSCLC

Has been most recently received regimen including an ICI (anti PD-1 antibodies, anti PD-L1 antibodies or anti CTLA-4 antibodies) and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotherapy followed by checkpoint inhibitor therapy), and all of the following criteria must be met: Received at least 2 doses at the most recent ICI therapy; Radiographic complete response or partial response based on investigator assessment with ICI therapy; Documented radiographic disease progression with above most recently received regimen

Must have received: systemic chemotherapy — advanced or metastatic gastric or gastroesophageal junction cancer

Has received 2-4 standard regimens listed below and has demonstrated disease progression according to imaging test during the most recent treatment or within 12 weeks after the final dose

Must have received: systemic chemotherapy (fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF monoclonal antibody) — advanced CRC

Prior treatment regimens must have included a fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody

Must have received: anti-EGFR monoclonal antibody — advanced CRC, RAS wild-type

For RAS wild-type patients, an anti-EGFR monoclonal antibody must have included in addition to above

Must have received: immune checkpoint inhibitor (anti PD-1 antibodies, anti PD-L1 antibodies, anti CTLA-4 antibodies) — advanced or metastatic NSCLC

Has been received one regimen of ICI monotherapy or combination therapy (anti PD-1 antibodies, anti PD-L1 antibodies or anti CTLA-4 antibodies), and all of the following criteria must be met: Received at least 2 doses of the ICI therapy; Documented radiographic disease progression with or after ICI therapy

Cannot have received: immune checkpoint inhibitor (anti-PD-L1, anti-PD-1, anti-CTLA-4)

Exception: except for cohort B-3, C-1, D-1 tolerability part and E-1

Prior treatment with an anti-PD-L1 anti-PD-1, anti-CTLA-4, or other ICI or agonist as monotherapy or in combination (except for cohort B-3, C-1, D-1 tolerability part and E-1).